News
FTRE
17.65
-0.34%
-0.06
Fortrea Holdings (FTRE) Could Be 47% Undervalued On New CFO And Reiterated Guidance
Simply Wall St · 12h ago
Fortrea Appoints New CFO and Reaffirms 2026 Outlook
TipRanks · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs 
Reuters · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber 
Reuters · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Fortrea, Nuvation Bio, Acadia Pharmaceuticals 
Reuters · 2d ago
Morning Movers: Shares of On Semi, Synaptics diverge after $7B transaction
TipRanks · 2d ago
BUZZ-Fortrea slips after new CFO appointment
Reuters · 2d ago
Fortrea Holdings CFO to Depart, Successor to Join in July
Dow Jones · 2d ago
Fortrea Appoints Jason Knoblauch To Succeed Jill McConnell As CFO
NASDAQ · 2d ago
Fortrea names Jason Knoblauch CFO, succeeding Jill McConnell
PUBT · 2d ago
Fortrea CFO Jill McConnell to step down, Jason Knoblauch to succeed
TipRanks · 2d ago
Fortrea Reiterates FY26 Guidance, Targeting Revenues In Range Of $2.550B-$2.650B, And Adjusted EBITDA Of $190M-$220M
Benzinga · 2d ago
Fortrea Appoints Jason Knoblauch As CFO, Effective July 6, Succeeding Jill Mcconnell
Benzinga · 2d ago
*Fortrea Holdings Backs FY Guidance of Adj. Ebitda of $190M-$220M >FTRE
Dow Jones · 2d ago
*Fortrea Holdings Reiterates Its Guidance for Full Yr 2026 >FTRE
Dow Jones · 2d ago
*Fortrea Holdings Backs FY Rev $2.55B-$2.65B >FTRE
Dow Jones · 2d ago
*Fortrea Holdings Knoblauch Will Succeed Jill McConnell >FTRE
Dow Jones · 2d ago
*Fortrea Holdings: McConnell Is Stepping Dn >FTRE
Dow Jones · 2d ago
Fortrea reiterates 2026 revenue outlook of $2.55 billion-$2.65 billion
PUBT · 2d ago
FORTREA HOLDINGS - REITERATES FY2026 REVENUE GUIDANCE OF $2.55 BLN-$2.65 BLN AND ADJ EBITDA OF $190 MLN-$220 MLN
Reuters · 2d ago
More
Webull provides a variety of real-time FTRE stock news. You can receive the latest news about Fortrea Holdings through multiple platforms. This information may help you make smarter investment decisions.
About FTRE
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.